Genomics Reporting Implementation Guide
3.0.0 - STU3 International flag

This page is part of the Genetic Reporting Implementation Guide (v3.0.0: STU3) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

: PGxRecEx03 - JSON Representation

Raw json | Download

{
  "resourceType" : "Task",
  "id" : "PGxRecEx03",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Task PGxRecEx03</b></p><a name=\"PGxRecEx03\"> </a><a name=\"hcPGxRecEx03\"> </a><a name=\"PGxRecEx03-en-US\"> </a><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title=\"Codes:{http://loinc.org LA26422-8}\">Decrease dose</span></p><p><b>description</b>: For citalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Adam B. Everyman  Male, DoB: 1951-01-20 ( Medical Record Number: m123\u00a0(use:\u00a0usual,\u00a0))</a></p><p><b>reasonReference</b>: <a href=\"Observation-TxImp03.html\">Poor metabolizer</a></p></div>"
  },
  "status" : "requested",
  "intent" : "proposal",
  "code" : {
    "coding" : [
      {
        "system" : "http://loinc.org",
        "code" : "LA26422-8",
        "display" : "Decrease dose"
      }
    ]
  },
  "description" : "For citalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.",
  "for" : {
    🔗 "reference" : "Patient/CGPatientExample01"
  },
  "reasonReference" : {
    🔗 "reference" : "Observation/TxImp03",
    "display" : "Poor metabolizer"
  }
}